Does the media favor VTRS or TVTX?

In the previous week, Travere Therapeutics had 6 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Travere Therapeutics and 4 mentions for Viatris. Travere Therapeutics' average media sentiment score of 1.49 beat Viatris' score of 0.47 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TVTX or GMAB?

In the previous week, Travere Therapeutics and Travere Therapeutics both had 10 articles in the media. Travere Therapeutics' average media sentiment score of 1.49 beat Genmab A/S's score of 1.21 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TVTX or BBIO?

In the previous week, BridgeBio Pharma had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 11 mentions for BridgeBio Pharma and 10 mentions for Travere Therapeutics. BridgeBio Pharma's average media sentiment score of 1.56 beat Travere Therapeutics' score of 1.49 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer ASND or TVTX?

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 10 articles in the media. Ascendis Pharma A/S's average media sentiment score of 1.73 beat Travere Therapeutics' score of 1.49 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TVTX or ELAN?

In the previous week, Travere Therapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 10 mentions for Travere Therapeutics and 9 mentions for Elanco Animal Health. Travere Therapeutics' average media sentiment score of 1.49 beat Elanco Animal Health's score of 1.08 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Travere Therapeutics (TVTX) Competitors

$56.68 -0.68 (-1.19%)

Closing price 07/27/2026 04:00 PM Eastern

Extended Trading

$58.44 +1.76 (+3.10%)

As of 04:03 AM Eastern

Compare

TVTX vs. VTRS, GMAB, BBIO, ASND, and ELAN

Should you buy Travere Therapeutics stock or one of its competitors? MarketBeat compares Travere Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Travere Therapeutics include Viatris (VTRS), Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Travere Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Travere Therapeutics has lower revenue, but higher earnings than Viatris. Travere Therapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.56B	1.41	-$3.51B	-$0.26	N/A
Travere Therapeutics	$536.20M	9.83	-$25.55M	-$0.23	N/A

Viatris has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

In the previous week, Travere Therapeutics had 6 more articles in the media than Viatris. MarketBeat recorded 10 mentions for Travere Therapeutics and 4 mentions for Viatris. Travere Therapeutics' average media sentiment score of 1.49 beat Viatris' score of 0.47 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris has a net margin of -2.04% compared to Travere Therapeutics' net margin of -4.00%. Viatris' return on equity of 19.04% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Viatris presently has a consensus target price of $17.50, indicating a potential downside of 0.79%. Travere Therapeutics has a consensus target price of $52.08, indicating a potential downside of 8.11%. Given Viatris' higher possible upside, research analysts clearly believe Viatris is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

79.9% of Viatris shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Travere Therapeutics beats Viatris on 9 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Genmab A/S?

Travere Therapeutics (NASDAQ:TVTX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Travere Therapeutics has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$536.20M	9.83	-$25.55M	-$0.23	N/A
Genmab A/S	$3.72B	4.83	$963M	$1.32	21.82

Travere Therapeutics presently has a consensus target price of $52.08, indicating a potential downside of 8.11%. Genmab A/S has a consensus target price of $39.28, indicating a potential upside of 36.38%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts clearly believe Genmab A/S is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Travere Therapeutics and Travere Therapeutics both had 10 articles in the media. Travere Therapeutics' average media sentiment score of 1.49 beat Genmab A/S's score of 1.21 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Travere Therapeutics' net margin of -4.00%. Genmab A/S's return on equity of 15.34% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Genmab A/S	21.05%	15.34%	8.94%

7.1% of Genmab A/S shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Genmab A/S beats Travere Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to BridgeBio Pharma?

Travere Therapeutics (NASDAQ:TVTX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Travere Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Travere Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$536.20M	9.83	-$25.55M	-$0.23	N/A
BridgeBio Pharma	$579.96M	28.41	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 11 mentions for BridgeBio Pharma and 10 mentions for Travere Therapeutics. BridgeBio Pharma's average media sentiment score of 1.56 beat Travere Therapeutics' score of 1.49 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Travere Therapeutics has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Travere Therapeutics has a net margin of -4.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
BridgeBio Pharma	-124.42%	N/A	-65.81%

99.8% of BridgeBio Pharma shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Travere Therapeutics currently has a consensus price target of $52.08, indicating a potential downside of 8.11%. BridgeBio Pharma has a consensus price target of $95.21, indicating a potential upside of 13.18%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

BridgeBio Pharma beats Travere Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Ascendis Pharma A/S has a net margin of 57.87% compared to Travere Therapeutics' net margin of -4.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Ascendis Pharma A/S currently has a consensus target price of $296.72, suggesting a potential upside of 17.09%. Travere Therapeutics has a consensus target price of $52.08, suggesting a potential downside of 8.11%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Ascendis Pharma A/S has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 10 articles in the media. Ascendis Pharma A/S's average media sentiment score of 1.73 beat Travere Therapeutics' score of 1.49 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Travere Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.41	-$258M	$8.67	29.23
Travere Therapeutics	$536.20M	9.83	-$25.55M	-$0.23	N/A

Summary

Ascendis Pharma A/S beats Travere Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Travere Therapeutics compare to Elanco Animal Health?

Travere Therapeutics (NASDAQ:TVTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Travere Therapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 10 mentions for Travere Therapeutics and 9 mentions for Elanco Animal Health. Travere Therapeutics' average media sentiment score of 1.49 beat Elanco Animal Health's score of 1.08 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics presently has a consensus price target of $52.08, indicating a potential downside of 8.11%. Elanco Animal Health has a consensus price target of $28.73, indicating a potential upside of 12.73%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Travere Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Travere Therapeutics has a net margin of -4.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Elanco Animal Health	-4.95%	7.42%	3.66%

97.5% of Elanco Animal Health shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Travere Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Travere Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$536.20M	9.83	-$25.55M	-$0.23	N/A
Elanco Animal Health	$4.89B	2.60	-$232M	-$0.50	N/A

Summary

Elanco Animal Health beats Travere Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Travere Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVTX vs. The Competition

Export

Metric	Travere Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.33B	$3.67B	$6.90B	$12.17B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	-246.42	21.28	27.03	23.74
Price / Sales	9.83	178.86	495.42	79.01
Price / Cash	158.39	59.51	26.39	46.67
Price / Book	44.28	7.96	10.36	6.16
Net Income	-$25.55M	$23.81M	$3.60B	$331.26M
7 Day Performance	0.18%	-3.15%	-1.64%	-0.71%
1 Month Performance	-3.69%	-3.93%	-2.57%	-2.52%
1 Year Performance	268.05%	33.83%	18.63%	14.76%

Travere Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVTX Travere Therapeutics	2.0233 of 5 stars	$56.68 -1.2%	$52.08 -8.1%	+270.0%	$5.33B	$536.20M	N/A	460	News Coverage Positive News
VTRS Viatris	2.4266 of 5 stars	$17.66 +2.4%	$17.50 -0.9%	+87.5%	$20.55B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.7403 of 5 stars	$29.00 +0.4%	$39.28 +35.4%	+23.1%	$18.06B	$3.72B	21.95	3,029
BBIO BridgeBio Pharma	2.9593 of 5 stars	$84.46 +0.5%	$95.21 +12.7%	+81.7%	$16.54B	$502.08M	N/A	400	Positive News Upcoming Earnings
ASND Ascendis Pharma A/S	4.6922 of 5 stars	$253.97 +0.0%	$296.72 +16.8%	+51.3%	$15.85B	$865.78M	29.30	1,189	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVTX) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Competitors

TVTX vs. VTRS, GMAB, BBIO, ASND, and ELAN

How does Travere Therapeutics compare to Viatris?

Summary

How does Travere Therapeutics compare to Genmab A/S?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Summary

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Travere Therapeutics compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Travere Therapeutics (TVTX) Competitors

TVTX vs. VTRS, GMAB, BBIO, ASND, and ELAN

How does Travere Therapeutics compare to Viatris?

Which has better valuation & earnings, VTRS or TVTX?

Which has more risk and volatility, VTRS or TVTX?

Does the media favor VTRS or TVTX?

Is VTRS or TVTX more profitable?

Do analysts recommend VTRS or TVTX?

Do institutionals & insiders believe in VTRS or TVTX?

Summary

How does Travere Therapeutics compare to Genmab A/S?

Which has more volatility and risk, TVTX or GMAB?

Which has better earnings and valuation, TVTX or GMAB?

Do analysts prefer TVTX or GMAB?

Does the media prefer TVTX or GMAB?

Is TVTX or GMAB more profitable?

Do institutionals and insiders believe in TVTX or GMAB?

Summary

How does Travere Therapeutics compare to BridgeBio Pharma?

Which has higher valuation and earnings, TVTX or BBIO?

Does the media prefer TVTX or BBIO?

Which has more volatility & risk, TVTX or BBIO?

Is TVTX or BBIO more profitable?

Do institutionals & insiders believe in TVTX or BBIO?

Do analysts prefer TVTX or BBIO?

Summary

How does Travere Therapeutics compare to Ascendis Pharma A/S?

Is ASND or TVTX more profitable?

Do analysts prefer ASND or TVTX?

Which has more volatility and risk, ASND or TVTX?

Does the media prefer ASND or TVTX?

Which has better valuation and earnings, ASND or TVTX?

Summary

How does Travere Therapeutics compare to Elanco Animal Health?

Does the media prefer TVTX or ELAN?

Do analysts recommend TVTX or ELAN?

Which has more volatility and risk, TVTX or ELAN?

Is TVTX or ELAN more profitable?

Do insiders & institutionals believe in TVTX or ELAN?

Which has better earnings & valuation, TVTX or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX vs. The Competition

Travere Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools